Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer

Triple-negative breast cancer (TNBC) is the deadliest form of breast cancer. Unlike other types of breast cancer that can be effectively treated by targeted therapies, no such targeted therapy exists for all TNBC patients. The ADAR1 enzyme carries out A-to-I editing of RNA to prevent sensing of endo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kung, Che-Pei, Cottrell, Kyle A., Ryu, Sua, Bramel, Emily R., Kladney, Raleigh D., Bross, Emily A., Freeman, Eric C., Sabloak, Thwisha, Maggi, Leonard, Weber, Jason D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796950/
https://www.ncbi.nlm.nih.gov/pubmed/33110236
http://dx.doi.org/10.1038/s41388-020-01515-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796950/
https://www.ncbi.nlm.nih.gov/pubmed/33110236
http://dx.doi.org/10.1038/s41388-020-01515-5

Ejemplares similares